What is HC Wainwright’s Estimate for ORKA FY2024 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Investment analysts at HC Wainwright lowered their FY2024 EPS estimates for Oruka Therapeutics in a research note issued on Monday, November 25th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($2.24) per share for the year, down from their previous forecast of ($1.56). HC Wainwright has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.98) EPS.

Other research analysts have also issued reports about the company. Lifesci Capital began coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective for the company. Leerink Partners initiated coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 target price for the company. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Finally, TD Cowen assumed coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating for the company. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Oruka Therapeutics has an average rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $20.26 on Wednesday. The firm has a market cap of $709.08 million, a PE ratio of -3.24 and a beta of 0.87. Oruka Therapeutics has a 1 year low of $18.20 and a 1 year high of $53.88. The stock has a 50 day moving average of $25.76.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC bought a new stake in shares of Oruka Therapeutics during the third quarter valued at approximately $114,763,000. RTW Investments LP bought a new position in Oruka Therapeutics in the 3rd quarter worth approximately $45,359,000. Franklin Resources Inc. acquired a new position in Oruka Therapeutics during the 3rd quarter worth $17,661,000. Braidwell LP bought a new position in Oruka Therapeutics in the 3rd quarter valued at $12,640,000. Finally, Great Point Partners LLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at $12,614,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.